Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Matthew L. Meyerson, MD, PhD


Researcher

No Ratings Available - Why Not?

Researcher

  • Professor of Pathology, Harvard Medical School

Contact Information

  • Office Phone Number617-632-4768
  • Fax617-582-7880

Bio

Dr. Meyerson received his MD in 1993 and PhD in 1994 from Harvard University. After a residency in clinical pathology at Massachusetts General Hospital and a research fellowship with Dr. Robert Weinberg at the Whitehead Institute, he joined DFCI in 1998. Dr. Meyerson has concentrated on using genomic approaches to understand the biology and genetics of human lung carcinomas. More broadly, his laboratory is focused on cancer genome discovery and pathogen discovery in human disease.Dr. Meyerson serves as Professor of Genetics at Dana-Farber Cancer Institute and Harvard Medical School, as Director of the Center for Cancer Genomics at DFCI, and as an Institute Member of the Broad Institute.

Recent Awards:

  • 23rd Annual Alfred G. Knudson Award in Cancer Genetics, National Cancer Institute 2019
  • Adi F. Gazdar Award for Translational Research, International Association for the Study of Lung Cancer 2018
  • Elected Member, National Academy of Medicine 2018
  • Han-Mo Koo Memorial Award, Van Andel Research Institute 2016
  • American Cancer Society Research Professorship 2015
  • Outstanding Investigator Award, National Cancer Institute 2015
  • Claire W. and Richard P. Morse Award, Dana-Farber Cancer Institute 2013
  • Ilchun Memorial Award, Korean Society of Biochemistry and Molecular Biology 2012
  • Caine Holter Hope Now Award, Uniting against Lung Cancer Foundation 2011
  • American Association for Cancer Research Team Science Award 2010
  • Paul Marks Prize in Cancer Research 2009
  • Career Investigator of the American Lung Association 2005
  • Tisch Family Outstanding Achievement Award in Translational Cancer Science 2004
  • Pew Scholar in the Biomedical Sciences 1999

Research

Genomic and functional studies of lung and other cancers

Somatic genetic alterations in cancer: We use genome-scale approaches to discover chromosomal alterations and cancer-causing mutations.  I am a principal investigator for NCI’s “The Cancer Genome Atlas” project for comprehensive cancer genome characterization; this work is based at the Broad Institute. This year, we are publishing numerous manuscripts from TCGA studies; I am co-chair of the lung cancer disease working group for TCGA and corresponding author of the submitted manuscript on squamous cell lung carcinoma, in which we identified loss-of-function HLA-A mutations.

We developed the use of single-nucleotide polymorphism (SNP) arrays for human cancer genome analysis (Lindblad-Toh et al., 2000).   We have now defined both lineage-specific and cancer-universal regions of amplification and deletion by SNP array analysis of over 2,500 cancer DNAs. Using SNP arrays, we identified the most common DNA amplification in lung adenocarcinoma, which targets the NKX2-1 pneumocyte-specifying transcription factor (Weir et al., 2007), common amplification of the SOX2 transcription factor in squamous cell carcinomas (Bass et al., 2009), and amplification of anti-apoptotic genes including MCL1,across multiple human cancers (Beroukhim et al., 2010).

Our cancer sequencing projects identified mutations in the epidermal growth factor receptor tyrosine kinase gene, EGFR, in lung adenocarcinomas, associated with clinical response to gefitinib and erlotinib (Paez et al., 2004), and in glioblastoma (Lee et al., 2006). We also identified activating mutations of FGFR2 in multiple cancers (Dutt et al., 2008) and of ALK in glioblastoma (George et al., 2008).  With our colleagues, we recently reported statistically significant mutation of 26 genes in lung adenocarcinoma (Ding et al., 2008).  In addition, we pioneered the use of single-template sequencing in cancer genome analysis (Thomas et al., 2006), which we are now applying widely.  Ongoing projects have identified mutation of MAP3K1 and CBFB and translocation of AKT3 in breast carcinoma (Banerji et al., 2012), translocations of the TCF7L2 gene in colon carcinoma (Bass et al., 2011), and mutations of multiple genes including U2AF1 and RBM10 in lung adenocarcinoma (Imielinski et al., 2012).

Functional analysis of lung cancer genes: We study oncogenic transformation by the major oncogenes that cause lung cancer, including EGFR and NKX2-1. For EGFR, we demonstrated the concept of mutation-selective therapy: distinct mutations are differentially sensitive or resistant to inhibitors (Greulich et al., 2005) and transformed cells bearing distinct mutations can most effectively be killed by different small molecule inhibitors (Yuza et al., 2007).  For NKX2-1, we have now identified LMO3 as a downstream target (Watanabe et al., 2013).  We have also recently identified multiple drug-sensitive alterations in the squamous cell lung cancer genome: mutations of DDR2 (Hammerman et al., 2011), FGFR2 and FGFR3 (Liao et al., 2013) and amplifications of FGFR1 (Dutt et al., 2011).

Tumor suppressor proteins and chromatin modification: We showed that several endocrine tumor suppressor proteins, including menin and parafibromin, are associated with histone methyltransferases (Hughes et al., 2004; Rozenblatt-Rosen et al., 2005). We are now working to modulate histone methylation activity for treating endocrine tumors and leukemias, and have showed that deletion of the Rbp2 histone demethylase can reverse tumorigenesis by loss of the menin tumor suppressor (Lin et al., 2011).

Discovery of pathogenic microbes: We developed a genomic approach to discover microbial sequences in human disease, by sequencing nucleic acids from diseased tissues followed by computational subtraction of human sequences (Weber et al., 2002). We and others have applied our approach to cancers, inflammatory and auto-immune diseases. Recently, we have completed a new software approach for identifying pathogens using next-generation sequencing data (Kostic et al., 2011), have identified an association of Fusobacterium species with colorectal carcinoma (Kostic et al., 2012) and have demonstrated that Fusobacterium infection potentiates lung cancer in mouse models (Kostic et al., 2013). Finally, we have recently identified infection with Bradyrhizobium enterica in transplant-associated cord colitis syndrome (Bhatt et al., 2013).

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun. 2021 07 16; 12(1):4375.
View in: PubMed

Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 Jul 14; 13(1):114.
View in: PubMed

Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat Genet. 2021 06; 53(6):881-894.
View in: PubMed

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Apr 29.
View in: PubMed

Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut. 2021 Mar 31.
View in: PubMed

Characterization of Plasmacytoid Dendritic Cells, Microbial Sequences, and Identification of a Candidate Public T-Cell Clone in Kikuchi-Fujimoto Disease. Pediatr Dev Pathol. 2021 May-Jun; 24(3):193-205.
View in: PubMed

Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 02; 34(5):108707.
View in: PubMed

Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells. Sci Immunol. 2021 Jan 22; 6(55).
View in: PubMed

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 Mar 15; 27(6):1695-1705.
View in: PubMed

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov. 2021 Mar; 11(3):591-598.
View in: PubMed

Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2. Genome Med. 2020 12 01; 12(1):108.
View in: PubMed

Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2020 Nov 28.
View in: PubMed

Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 Nov 27; 295(48):16464-16467.
View in: PubMed

Bacterial invaders drive CRC progression. Sci Signal. 2020 08 11; 13(644).
View in: PubMed

Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clin Cancer Res. 2020 09 01; 26(17):4651-4660.
View in: PubMed

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 10; 31(10):1366-1375.
View in: PubMed

Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer. 2020 09; 59(9):535-539.
View in: PubMed

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814.
View in: PubMed

Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 03 24; 4(6):1006-1011.
View in: PubMed

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
View in: PubMed

Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020 04; 580(7802):269-273.
View in: PubMed

Genomic basis for RNA alterations in cancer. Nature. 2020 02; 578(7793):129-136.
View in: PubMed

Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 03 13; 295(11):3431-3446.
View in: PubMed

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020 Feb; 1(2):235-248.
View in: PubMed

Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma. Mol Cancer Res. 2020 04; 18(4):574-584.
View in: PubMed

Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun. 2019 11 29; 10(1):5472.
View in: PubMed

Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. ACS Med Chem Lett. 2019 Nov 14; 10(11):1537-1542.
View in: PubMed

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019 09 05; 10(1):3991.
View in: PubMed

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293.
View in: PubMed

Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer. Cancer Res. 2019 03 15; 79(6):1038-1040.
View in: PubMed

A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019 05 01; 79(9):2352-2366.
View in: PubMed

Commensal Microbiota Promote Lung Cancer Development via ?d T Cells. Cell. 2019 02 21; 176(5):998-1013.e16.
View in: PubMed

Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma. Mol Cancer Res. 2019 04; 17(4):1002-1012.
View in: PubMed

Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019 01; 565(7738):E5-E6.
View in: PubMed

Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450.
View in: PubMed

GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics. 2018 12 15; 34(24):4287-4289.
View in: PubMed

Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21).
View in: PubMed

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
View in: PubMed

The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol. 2018 12; 188(12):2839-2852.
View in: PubMed

Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res. 2018 11; 6(11):1327-1336.
View in: PubMed

Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387.
View in: PubMed

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
View in: PubMed

Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
View in: PubMed

Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
View in: PubMed

Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
View in: PubMed

Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
View in: PubMed

Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
View in: PubMed

Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943.
View in: PubMed

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19.
View in: PubMed

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
View in: PubMed

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. . 2018 07; 17(7):1526-1539.
View in: PubMed

Mechanistic Insights into Transmissible Cancers of Mammals. Cancer Cell. 2018 04 09; 33(4):543-544.
View in: PubMed

Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10.
View in: PubMed

Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018 04 09; 33(4):676-689.e3.
View in: PubMed

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
View in: PubMed

Landscapes of childhood tumours. Nature. 2018 03 15; 555(7696):316-317.
View in: PubMed

SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591.
View in: PubMed

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
View in: PubMed

Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants. Int J Cancer. 2018 08 01; 143(3):679-685.
View in: PubMed

Landscapes of childhood tumours. Nature. 2018 Mar; 555(7696):316-317.
View in: PubMed

Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. BMC Genomics. 2018 01 08; 19(1):30.
View in: PubMed

High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2017 12 11; 32(6):884.
View in: PubMed

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448.
View in: PubMed

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
View in: PubMed

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov. 2018 01; 8(1):59-73.
View in: PubMed

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
View in: PubMed

Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125.
View in: PubMed

Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Res. 2017 12 15; 77(24):6987-6998.
View in: PubMed

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2017 06 30; 7:46873.
View in: PubMed

Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60.
View in: PubMed

Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncol. 2017 Jun 01; 3(6):801-809.
View in: PubMed

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 08 15; 77(16):4498-4505.
View in: PubMed

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in: PubMed

Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. Cell. 2017 01 26; 168(3):460-472.e14.
View in: PubMed

Copy number alterations unmasked as enhancer hijackers. Nat Genet. 2016 12 28; 49(1):5-6.
View in: PubMed

Emerging Concepts and Technologies for the Discovery of Microorganisms Involved in Human Disease. Annu Rev Pathol. 2017 Jan 24; 12:217-244.
View in: PubMed

Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
View in: PubMed

Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol. 2016 Nov 03; 7(11):e200.
View in: PubMed

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016 11 02; 8(363):363ra147.
View in: PubMed

Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. . 2016 12; 17(12):1274-1281.
View in: PubMed

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 08 08; 30(2):363.
View in: PubMed

Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genet. 2016 08; 12(8):e1006242.
View in: PubMed

High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2016 08 08; 30(2):214-228.
View in: PubMed

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 06 24; 6:27960.
View in: PubMed

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
View in: PubMed

Metagenomic Characterization of Microbial Communities In Situ Within the Deeper Layers of the Ileum in Crohn's Disease. Cell Mol Gastroenterol Hepatol. 2016 Sep; 2(5):563-566.e5.
View in: PubMed

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 05 10; 6:25521.
View in: PubMed

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16.
View in: PubMed

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 05 09; 29(5):723-736.
View in: PubMed

VariantBam: filtering and profiling of next-generational sequencing data using region-specific rules. Bioinformatics. 2016 07 01; 32(13):2029-31.
View in: PubMed

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28; 164(3):550-63.
View in: PubMed

BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016 Jan; 131(1):147-50.
View in: PubMed

Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016 Feb; 48(2):176-82.
View in: PubMed

Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb; 12(2):102-8.
View in: PubMed

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016 Feb; 14(2):207-15.
View in: PubMed

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
View in: PubMed

Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the ?-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000539.
View in: PubMed

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in: PubMed

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. ACS Chem Biol. 2015 Dec 18; 10(12):2687-96.
View in: PubMed

Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 12; 65(12):1973-1980.
View in: PubMed

Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol. 2015 Sep; 22(9):703-711.
View in: PubMed

Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in: PubMed

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. . 2015 Oct; 14(10):2382-2389.
View in: PubMed

Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015 Oct; 54(10):606-15.
View in: PubMed

Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clin Cancer Res. 2016 Jan 01; 22(1):250-8.
View in: PubMed

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
View in: PubMed

Chromothripsis from DNA damage in micronuclei. Nature. 2015 Jun 11; 522(7555):179-84.
View in: PubMed

Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015 May 07; 161(4):933-45.
View in: PubMed

Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015 May; 10(5):838-843.
View in: PubMed

Calibrating genomic and allelic coverage bias in single-cell sequencing. Nat Commun. 2015 Apr 16; 6:6822.
View in: PubMed

Pugh et al. reply. Nature. 2015 Apr 16; 520(7547):E12-4.
View in: PubMed

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242.
View in: PubMed

The tumor virus landscape of AIDS-related lymphomas. Blood. 2015 May 14; 125(20):e14-22.
View in: PubMed

Oncotator: cancer variant annotation tool. Hum Mutat. 2015 Apr; 36(4):E2423-9.
View in: PubMed

A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015 Mar 09; 27(3):397-408.
View in: PubMed

Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer. 2015 Aug 15; 137(4):776-83.
View in: PubMed

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015 Mar; 25(3):316-27.
View in: PubMed

Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167.
View in: PubMed

Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol Cancer Res. 2015 Apr; 13(4):689-98.
View in: PubMed

Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18661-6.
View in: PubMed

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15; 75(2):264-9.
View in: PubMed

BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19.
View in: PubMed

Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. J Virol. 2015 Jan; 89(1):857-62.
View in: PubMed

Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9.
View in: PubMed

Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck. 2015 Nov; 37(11):1642-9.
View in: PubMed

The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 08; 26(3):319-330.
View in: PubMed

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014 Sep 01; 74(17):4676-84.
View in: PubMed

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecol Oncol. 2014 Sep; 134(3):599-606.
View in: PubMed

The p53 pathway and ancestral progenitors are associated with tumor recurrence in glioblastoma. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii3.
View in: PubMed

In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol. 2014 Jul; 66(7):1939-44.
View in: PubMed

Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014 Nov 06; 33(45):5295-302.
View in: PubMed

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
View in: PubMed

EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014 Aug; 4(8):956-71.
View in: PubMed

Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res. 2014 Jul; 24(7):1053-63.
View in: PubMed

Breaking down RET breakpoints in lung adenocarcinoma. J Thorac Oncol. 2014 May; 9(5):590-2.
View in: PubMed

Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014 Apr 24; 5:3728.
View in: PubMed

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
View in: PubMed

SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014 Apr; 124(4):1636-45.
View in: PubMed

A121: in search of infectious triggers of periodic Fever, aphthous stomatitis, pharyngitis and adenitis syndrome. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S158.
View in: PubMed

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014 Apr; 124(4):1582-6.
View in: PubMed

A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014; 9(1):e87361.
View in: PubMed

Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014 Aug 28; 33(35):4418-23.
View in: PubMed

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014 Feb; 4(2):216-31.
View in: PubMed

Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501.
View in: PubMed

Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20; 506(7488):371-5.
View in: PubMed

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177.
View in: PubMed

Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014 Jan 10; 32(2):121-8.
View in: PubMed

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. . 2014 Feb; 13(2):475-82.
View in: PubMed

DNA sequencing of cancer: what have we learned? Annu Rev Med. 2014; 65:63-79.
View in: PubMed

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014 Jan 03; 53(1):199-204.
View in: PubMed

Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 11 07; 369(19):1867.
View in: PubMed

Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec; 45(12):1483-6.
View in: PubMed

The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10; 155(2):462-77.
View in: PubMed

Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
View in: PubMed

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20.
View in: PubMed

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63.
View in: PubMed

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15; 73(22):6770-9.
View in: PubMed

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950.
View in: PubMed

Microbes and inflammation in colorectal cancer. Cancer Immunol Res. 2013 Sep; 1(3):150-7.
View in: PubMed

Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013 Oct 15; 73(20):6289-98.
View in: PubMed

Signatures of mutational processes in human cancer. Nature. 2013 Aug 22; 500(7463):415-21.
View in: PubMed

Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. . 2013 Aug 14; 14(2):207-15.
View in: PubMed

Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 08; 369(6):517-28.
View in: PubMed

Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood. 2013 Sep 19; 122(12):2039-46.
View in: PubMed

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
View in: PubMed

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15; 73(16):5195-205.
View in: PubMed

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
View in: PubMed

Hopping between differentiation states in lung adenocarcinoma. Cancer Cell. 2013 Jun 10; 23(6):707-9.
View in: PubMed

A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013 May 31; 340(6136):1100-6.
View in: PubMed

Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
View in: PubMed

Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
View in: PubMed

Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 2013 Apr 25; 50(2):185-99.
View in: PubMed

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
View in: PubMed

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar; 31(3):213-9.
View in: PubMed

The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84.
View in: PubMed

Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15; 27(2):197-210.
View in: PubMed

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013 Feb; 45(2):131-2.
View in: PubMed

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan; 123(1):517-25.
View in: PubMed

Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. 2012 Dec; 1(4):293-300.
View in: PubMed

Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013 Feb; 23(2):228-35.
View in: PubMed

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20.
View in: PubMed

Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25.
View in: PubMed

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012 Oct; 44(10):1104-10.
View in: PubMed

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
View in: PubMed

Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5.
View in: PubMed

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
View in: PubMed

Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 02; 488(7409):49-56.
View in: PubMed

A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
View in: PubMed

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012 Sep 15; 18(18):4973-85.
View in: PubMed

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012 Sep 01; 72(17):4383-93.
View in: PubMed

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
View in: PubMed

Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012 Jul 06; 337(6090):104-9.
View in: PubMed

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9.
View in: PubMed

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
View in: PubMed

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May; 30(5):413-21.
View in: PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7.
View in: PubMed

Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proc Natl Acad Sci U S A. 2012 Mar 13; 109(11):4251-6.
View in: PubMed

Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7.
View in: PubMed

ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol. 2012 Mar 10; 30(8):878-9.
View in: PubMed

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
View in: PubMed

High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol. 2011 Nov 20; 29(12):1109-13.
View in: PubMed

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
View in: PubMed

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012 Feb; 22(2):292-8.
View in: PubMed

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25.
View in: PubMed

Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011 Dec 15; 71(24):7587-96.
View in: PubMed

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
View in: PubMed

Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311.
View in: PubMed

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011 Jul 31; 43(9):869-74.
View in: PubMed

The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
View in: PubMed

Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13379-86.
View in: PubMed

Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 2011 Jul 15; 25(14):1470-5.
View in: PubMed

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7.
View in: PubMed

SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell. 2011 Jul 08; 43(1):45-56.
View in: PubMed

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011; 6(6):e20351.
View in: PubMed

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89.
View in: PubMed

Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502.
View in: PubMed

PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol. 2011 May; 29(5):393-6.
View in: PubMed

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41.
View in: PubMed

Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011 May 05; 473(7345):101-4.
View in: PubMed

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011 Jul; 24(7):944-53.
View in: PubMed

Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
View in: PubMed

Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55.
View in: PubMed

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
View in: PubMed

Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 Apr 10; 29(11):1415-23.
View in: PubMed

Transcriptional activators enhance polyadenylation of mRNA precursors. Mol Cell. 2011 Feb 18; 41(4):409-18.
View in: PubMed

The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20.
View in: PubMed

The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS One. 2011 Jan 14; 6(1):e16119.
View in: PubMed

Cancer genomes evolve by pulverizing single chromosomes. Cell. 2011 Jan 07; 144(1):9-10.
View in: PubMed

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30.
View in: PubMed

A novel totivirus and piscine reovirus (PRV) in Atlantic salmon (Salmo salar) with cardiomyopathy syndrome (CMS). Virol J. 2010 Nov 10; 7:309.
View in: PubMed

Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010 Oct; 11(10):685-96.
View in: PubMed

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 2010 Oct 10; 28(29):4417-24.
View in: PubMed

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
View in: PubMed

Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23.
View in: PubMed

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010 Aug; 23(8):1061-7.
View in: PubMed

A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol. 2010 Mar 26; 17(3):285-95.
View in: PubMed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
View in: PubMed

Integrative analysis of the melanoma transcriptome. Genome Res. 2010 Apr; 20(4):413-27.
View in: PubMed

The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
View in: PubMed

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19; 17(1):98-110.
View in: PubMed

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene. 2010 Mar 18; 29(11):1588-97.
View in: PubMed

Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
View in: PubMed

Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov; 8(21):2042-50.
View in: PubMed

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12.
View in: PubMed

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42.
View in: PubMed

In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol. 2009 Oct; 132(4):500-5.
View in: PubMed

Genome-wide association study in esophageal squamous cell carcinoma. Gastroenterology. 2009 Nov; 137(5):1573-6.
View in: PubMed

Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer. 2009 Oct 06; 101(7):1218-9; author reply 1220-1.
View in: PubMed

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13(8B):1977-1986.
View in: PubMed

Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 01; 69(11):4674-81.
View in: PubMed

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8.
View in: PubMed

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009 Jun; 119(6):1727-40.
View in: PubMed

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009 Apr 15; 69(8):3256-61.
View in: PubMed

Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer. 2009 Apr; 48(4):366-80.
View in: PubMed

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4834-9.
View in: PubMed

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009 Feb 15; 15(4):1417-27.
View in: PubMed

The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors. Proc Natl Acad Sci U S A. 2009 Jan 20; 106(3):755-60.
View in: PubMed

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):474-9.
View in: PubMed

TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol. 2009 Jan; 217(1):65-72.
View in: PubMed

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
View in: PubMed

High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods. 2009 Jan; 6(1):99-103.
View in: PubMed

Chromosomal deletions and progression of premalignant lesions: less is more. Cancer Prev Res (Phila). 2008 Nov; 1(6):404-8.
View in: PubMed

Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75.
View in: PubMed

Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8.
View in: PubMed

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51.
View in: PubMed

Functional copy-number alterations in cancer. PLoS One. 2008 Sep 11; 3(9):e3179.
View in: PubMed

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008 Dec; 135(6):1972-83, 1983.e1-11.
View in: PubMed

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008 Aug 15; 68(16):6779-88.
View in: PubMed

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug; 14(8):822-7.
View in: PubMed

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38.
View in: PubMed

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 01; 14(13):4275-83.
View in: PubMed

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer. 2008 Jul 22; 99(2):245-52.
View in: PubMed

Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008 Jun 24; 105(25):8713-7.
View in: PubMed

A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol. 2008 May 20; 26(15_suppl):7510.
View in: PubMed

Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics. 2008 Apr 21; 9:204.
View in: PubMed

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 07; 27(34):4702-11.
View in: PubMed

Adding pathogens by genomic subtraction. Nat Genet. 2008 Apr; 40(4):380-2.
View in: PubMed

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93.
View in: PubMed

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer. 2008 Mar; 47(3):253-9.
View in: PubMed

The T790M mutatation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad SCi USA. 2008; 105(6):2070-5.

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 01; 111(9):4788-96.
View in: PubMed

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
View in: PubMed

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol. 2008 Feb; 32(2):307-16.
View in: PubMed

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008 Feb 12; 105(6):2070-5.
View in: PubMed

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32.
View in: PubMed

Assessing the significance of chromosonal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007; 104(50):20007-12.

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
View in: PubMed

Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
View in: PubMed

Comment on "The consensus coding sequences of human breast and colorectal cancers". Science. 2007 Sep 14; 317(5844):1500.
View in: PubMed

LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10.
View in: PubMed

Cancer: broken genes in solid tumours. Nature. 2007 Aug 02; 448(7153):545-6.
View in: PubMed

The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3' processing and transcription termination. Genes Dev. 2007 Jul 15; 21(14):1779-89.
View in: PubMed

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007 Jul; 12(1):81-93.
View in: PubMed

Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
View in: PubMed

Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007 Mar; 11(3):217-27.
View in: PubMed

Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255.
View in: PubMed

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007 Jul 26; 26(34):5023-7.
View in: PubMed

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. . 2007 May; 6(5):661-7.
View in: PubMed

High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
View in: PubMed

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6.
View in: PubMed

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8.
View in: PubMed

Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98.
View in: PubMed

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485.
View in: PubMed

Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 2006 Nov 01; 24(31):5079-90.
View in: PubMed

Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol Cancer Res. 2006 Oct; 4(10):793-801.
View in: PubMed

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 Sep 01; 66(17):8337-41.
View in: PubMed

Genomic approaches to lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4384s-4391s.
View in: PubMed

Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s.
View in: PubMed

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
View in: PubMed

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006 Jul 01; 66(13):6487-91.
View in: PubMed

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
View in: PubMed

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006 Jul; 12(7):852-5.
View in: PubMed

Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2006 Jun 20; 24(18_suppl):7177.
View in: PubMed

C/EBP alpha mutations in lung cancer. Lung Cancer. 2006 Aug; 53(2):253-4.
View in: PubMed

Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006 May; 2(5):e41.
View in: PubMed

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006 May 16; 103(20):7817-22.
View in: PubMed

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006 Mar 15; 66(6):3162-8.
View in: PubMed

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8.
View in: PubMed

Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol. 2005 Nov; 1(6):e65.
View in: PubMed

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005 Oct 21; 123(2):207-18.
View in: PubMed

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
View in: PubMed

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74.
View in: PubMed

Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005 Oct 11; 102(41):14659-64.
View in: PubMed

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15; 65(16):7096-101.
View in: PubMed

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
View in: PubMed

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005 Jul 01; 65(13):5561-70.
View in: PubMed

Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol. 2005 May 10; 23(14):3219-26.
View in: PubMed

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
View in: PubMed

EGFR gene mutations: a call for global x global views of cancer. J Natl Cancer Inst. 2005 Mar 02; 97(5):326-8.
View in: PubMed

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
View in: PubMed

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):565-72.
View in: PubMed

Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A. 2005 Jan 18; 102(3):749-54.
View in: PubMed

The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005 Jan; 25(2):612-20.
View in: PubMed

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. J Clin Oncol. 2005 Jan 01; 23(1):235-7.
View in: PubMed

"Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harb Symp Quant Biol. 2005; 70:25-34.
View in: PubMed

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:73-81.
View in: PubMed

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004 Dec 15; 64(24):8816-20.
View in: PubMed

Somatic alterations in the human cancer genome. Cancer Cell. 2004 Nov; 6(5):433-8.
View in: PubMed

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004 Oct 15; 64(20):7241-4.
View in: PubMed

Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004 Sep; 2(9):489-94.
View in: PubMed

Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. Nucleic Acids Res. 2004 Aug 25; 32(15):e121.
View in: PubMed

Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture? J Clin Oncol. 2004 Aug 15; 22(16):3209-11.
View in: PubMed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in: PubMed

Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 2004 May 18; 32(9):e71.
View in: PubMed

An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004 May 01; 64(9):3060-71.
View in: PubMed

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
View in: PubMed

High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 08; 23(15):2716-26.
View in: PubMed

Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell. 2004 Feb 27; 13(4):587-97.
View in: PubMed

Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A. 2004 Feb 17; 101(7):1892-7.
View in: PubMed

Molecular classification and molecular genetics of human lung cancers. Semin Oncol. 2004 Feb; 31(1 Suppl 1):4-19.
View in: PubMed

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004 Jan 01; 64(1):64-71.
View in: PubMed

Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 2003 Aug 15; 63(16):4781-5.
View in: PubMed

Human genetic variation and disease. Lancet. 2003 Jul 26; 362(9380):259-60.
View in: PubMed

Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics. 2003 Mar; 81(3):329-35.
View in: PubMed

Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002 Dec 01; 62(23):7001-3.
View in: PubMed

Identification of foreign gene sequences by transcript filtering against the human genome. Nat Genet. 2002 Feb; 30(2):141-2.
View in: PubMed

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5.
View in: PubMed

Telomerase activation, cellular immortalization and cancer. Ann Med. 2001 Mar; 33(2):123-9.
View in: PubMed

Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000 Sep; 18(9):1001-5.
View in: PubMed

Role of telomerase in normal and cancer cells. J Clin Oncol. 2000 Jul; 18(13):2626-34.
View in: PubMed

Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas. Genes Chromosomes Cancer. 2000 Mar; 27(3):323-31.
View in: PubMed

Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct; 5(10):1164-70.
View in: PubMed

Telomerase enzyme activation and human cell immortalization. Toxicol Lett. 1998 Dec 28; 102-103:41-5.
View in: PubMed

Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun; 19(2):182-6.
View in: PubMed

Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 05; 16(9):1217-22.
View in: PubMed

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22; 90(4):785-95.
View in: PubMed

The catalytic subunit of yeast telomerase. Proc Natl Acad Sci U S A. 1997 Aug 19; 94(17):9202-7.
View in: PubMed

Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994 Mar; 14(3):2077-86.
View in: PubMed

Pulmonary embolism: comparison of MR images with radionuclide and angiographic studies. Radiology. 1994 Feb; 190(2):499-508.
View in: PubMed

A family of human cdc2-related protein kinases. EMBO J. 1992 Aug; 11(8):2909-17.
View in: PubMed

Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature. 1991 Sep 12; 353(6340):174-7.
View in: PubMed

The cyclin-dependent kinase family. Cold Spring Harb Symp Quant Biol. 1991; 56:177-86.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1540
Boston, MA 02215
Get Directions

Top